在线观看人与动牲交视频_夜夜高潮次次欢爽AV女_奇米在线视频观看_欧美精品七区_色悠久久综合网_少妇潮喷无码白浆水视频

北科生物Beike Biotechnology  
深圳市北科生物科技有限公司（簡稱北科生物），是中國專業從事干細胞基礎研究、臨床應用研究及干細胞技術服務的生物高科技企業。在干細胞臨床應用研究和技術服務等方面，北科生物始終和國際發展同步。北科生物對中國生物醫學技術的發展具有強烈的使命感，旨在通過對干細胞基礎研究和臨床應用技術的持續、深入研究，使中國的生物醫學產業在國際競爭中占據一席之地。

北科生物自2005年7月成立以來，憑借著其在干細胞基礎研究和臨床應用研究領域取得的積極成果，而備受國內外關注和好評。北科生物是一家擁有自主知識產權的生物企業，目前已擁有8項重要的發明專利，1項實用新型專利，其中2項獲得授權。2006年9月深圳市科技和信息局授予北科生物為深圳市高新技術企業。

北科生物目前擁有員工約430名，其中56%以上為技術人員，擁有在干細胞研究領域成果卓越的多位院士及國內外學者領銜的專業技術研發團隊。

北科生物在海內外投資成立了黑龍江省北科生物科技有限公司、遼寧北科生物科技有限公司、江蘇省北科生物科技有限公司、上海祥暉生物科技有限公司、湖北省北科生物科技有限公司、北科國際（香港）有限公司、Beike Biotech India Pvt. Ltd.（印度）和Beike-Siricell Holdings Inc.（泰國）。

北科生物一直孜孜不倦地在拓展新的產業發展思路，得到了政府各界的大力支持。江蘇北科即是借助政府各方面的支持，創建的一個嶄新的、具有突破性的技術平臺。江蘇北科下設中國醫藥城北科干細胞研究院，并獲得江蘇省科技廳批準成立江蘇省干細胞與生物治療公共技術服務平臺（下設江蘇省干細胞庫、江蘇省生物治療研究中心），獲得江蘇省發改委批準成立江蘇省干細胞與再生醫學工程中心，并且是江蘇省衛生廳批準的江蘇省干細胞與再生醫學基地的主要承建單位。同時，在2005年12月公司得到深圳市政府支持成立了深圳市北科細胞工程研究所，在2008年12月獲得深圳市科信局的立項支持成立了深圳市干細胞工程技術研究開發中心。

北科生物致力于干細胞技術從實驗室到臨床應用的一系列標準、規范和體系的建立和完善；致力于多種來源的成體干細胞的體外分離、培養、擴增、誘導、分化及鑒定的基礎研究和臨床應用研究；致力于多種干細胞組織工程產品的研究、開發，以及干細胞相關的藥物篩選平臺的建設；特別值得一提的是，在近兩年國內外在干細胞領域取得突破性進展的iPS技術領域，公司擁有自主知識產權并決定在該研究領域投入巨資。目前，北科生物已在全國各地建立了多個符合GMP標準的細胞實驗室，已啟動ISO9001 質量管理體系認證，并積極參照AABB/FACT的相關標準，對公司現有質控體系進行完善和提高。

截至2009年，北科干細胞技術已經治療病人6000多例，其中包括美國、加拿大、英國、匈牙利等40多個國家的500多名國外患者，獲得了顯著的治療效果。

北科生物已與清華大學深圳研究生院、香港中文大學、鄭州大學、匈牙利德布勒森大學及瑞典哥德堡大學等多所國內外知名學府建立了科研合作關系。這種廣泛的國際、國內科研合作，有利于發揮各自優勢，確立我們在干細胞基礎研究和臨床科研領域的國際領先地位。

北科生物將本著“嚴謹、創新、關愛、服務”的企業理念，為干細胞技術能夠為人類健康造福而不懈追求！

Beike Biotechnology is a leading biotechnology company whose scientists have been dedicated to the development and commercialization of adult stem cell therapies since 1999. The company currently produces a full line of stem cell products derived from umbilical cord, cord blood, and bone marrow stem cells. Beike's proprietary processing and quality assurance technologies prepare the cells for use in treating a variety of serious medical conditions including ataxia, brain injury, cerebral palsy, diabetic foot disease, lower limb ischemia, multiple sclerosis, muscular dystrophy, spinal cord injury, and optic nerve damage.

Beike's stem cells are derived from healthy donors who are carefully screened for transmissible diseases. The samples are additionally screened by government appointed blood banks and Beike’s specialized laboratories. The stem cells are then banked in state-of-the-art facilities and only utilized in partnership with the best hospitals and physicians.

Stringent quality control procedures are undertaken at each of Beike‘s eighteen laboratories. Some of the laboratories are located inside the research departments of hospitals while others are located directly inside government blood banks. Beike also has two large stand alone laboratories where both research and stem cell processing take place. Beike, in partnership with the regional government, maintains a bank for the storage of stem cells located in the China Medical City in the Jiangsu province. This storage facility is capable of storing cord blood, cord mesenchymal, and iPS cells. All of the laboratories are outfitted with modern equipment and have been fully certified by the relevant drug authorities.

Treatment protocols include injections of umbilical cord blood stem cells, cord mesenchymal stem cells, and bone marrow mesenchymal stem cells directly into the spinal cord fluid and intravenously. However, for ailments like spinal cord injuries, liver disease, heart disease, muscular dystrophy, and lower limb ischemia, the stem cells are delivered through injections directly into the damaged tissue as well as through standard methods. For many diseases, protocols include rehabilitation and physical therapy.

Stem cells work by providing the body with paracrine and cytokines as well as a variety of other cell factors. These help to encourage the following functions:

1. Immune system regulation
2. Reducing cell death
3. Stimulation of growth of the patient’s own stem cells
4. Neo-angiogenesis (the growth of blood vessels resulting in increased blood flow to damaged areas)
5. Scar tissue reduction
6. Improving the effective conduction of intercellular electrical signals and transduction

Our research for future treatments is focused mainly on iPS technology in partnership with various leading scientific groups including Tsinghua Unversity. Beike’s scientists and partners have authored nearly eighty publications in Chinese scientific journals as well as ongoing clinical studies since our first ALS trial program in 2001. We very much welcome cooperation with international partners to help verify the effectiveness of our treatments and protocols and to license other technologies for use throughout our network of twenty seven hospitals。

The company was founded with capital from Beijing University, Hong Kong University of Science and Technology, and Shenzhen City Hall. The formation of the company was also supported with grants from the China State National Fund. Since that time, additional capital has been provided by a variety of Chinese venture capital firms.In total, Beike has received over US$6 million in Chinese government grants including a grant for a joint laboratory in Shenzhen with Tsingua University to focus on the study of stem cell reprogramming.

Beike‘s head office is located in Shenzhen but the company also has offices in Beijing, Nanjing, Taizhou, and Qingdao.

Stem Cell Processing Information

Umbilical Cord Blood (UCB) Stem Cells

For most ailments such as CP, ataxia, ALS, autism, and optic nerve hypoplasia, Beike's protocols utilize UCB stem cells. Our UCB stem cell doses consist of three subsets of stem cells. These are hematopoietic stem cells, endothelial progenitor cells, and mesenchymal stem cells. As has been shown in numerous studies, hematopoietic stem cells and endothelial progenitor stem cells are likely to form tissues in the body. Mesenchymal stem cells can assist in the growth of chondrocytes (a type of cell critical to tissue renewal, particularly cartilage), liver cells, kidney cells, and neurons, and also conduct repairs in relation to vascular disorders within the brain, ocular areas, and throughout the body including the heart, kidney, and pancreas.

Umbilical Cord Mesenchymal (UC-MSC) Stem Cells

Some of Beike's protocols, inclu